Press release
Methylmalonic Acidemia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | HemoShear, LogicBio, Moderna, Selecta Biosciences, PTC Therapeutics, Poseida, VectivBio, CoA Therapeutics
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Methylmalonic Acidemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Methylmalonic Acidemia Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Methylmalonic Acidemia Therapeutics Market.
The report provides a detailed description of the Methylmalonic Acidemia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Methylmalonic Acidemia Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Methylmalonic Acidemia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Methylmalonic Acidemia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Methylmalonic Acidemia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Methylmalonic Acidemia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Methylmalonic Acidemia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Methylmalonic Acidemia Therapeutics Domain:
https://www.delveinsight.com/report-store/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Methylmalonic Acidemia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Methylmalonic Academia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
Request for Sample PDF to Understand More About the Methylmalonic Acidemia Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Methylmalonic Acidemia Therapeutics Analysis
Several major pharma and biotech companies are developing the Methylmalonic acidemia. Currently, HemoShear Therapeutics is leading the therapeutics market with its Methylmalonic Academia drug candidates in the most advanced stage of clinical development.
Methylmalonic Acidemia Companies in the Therapeutics Market Include:
• HemoShear Therapeutics
• LogicBio Therapeutics
• Moderna Therapeutics
• Selecta Biosciences
• PTC Therapeutics
• Poseida Therapeutics
• VectivBio AG
• CoA Therapeutics, Inc.
And Many Others
Emerging and Marketed Methylmalonic Acidemia Therapies Covered in the Report Include:
• HST5040: HemoShear Therapeutics
• LB-001: LogicBio Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Methylmalonic Acidemia Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Methylmalonic Acidemia Current Treatment Patterns
4. Methylmalonic Acidemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Methylmalonic Acidemia Late-Stage Products (Phase-III)
7. Methylmalonic Acidemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Methylmalonic Acidemia Discontinued Products
13. Methylmalonic Acidemia Product Profiles
14. Methylmalonic Acidemia Companies
15. Methylmalonic Acidemia Drugs
16. Dormant and Discontinued Products
17. Methylmalonic Acidemia Unmet Needs
18. Methylmalonic Acidemia Future Perspectives
19. Methylmalonic Acidemia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Healthcare Reports by DelveInsight
• Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market
• Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market
• Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market
• Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market
• Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market
• Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
• Respiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market
• Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market
• Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
• Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
• Traveler's Diarrhea Market
https://www.delveinsight.com/report-store/travelers-diarrhea-market
• Usher Syndrome Market
https://www.delveinsight.com/report-store/usher-syndrome-market
• Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market
• Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market
• Wide Neck Bifurcation Intracranial Aneurysms Market
https://www.delveinsight.com/report-store/wide-neck-bifurcation-intracranial-aneurysms-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Methylmalonic Acidemia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | HemoShear, LogicBio, Moderna, Selecta Biosciences, PTC Therapeutics, Poseida, VectivBio, CoA Therapeutics here
News-ID: 3118957 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Methylmalonic
Methylmalonic Acidemia Market trends, Diagnosis, and Treatment Landscape
Methylmalonic Acidemia (MMA) is a rare inherited metabolic disorder resulting from defects in the metabolism of certain amino acids, cholesterol, and fatty acids. It is typically caused by mutations in genes responsible for the enzyme methylmalonyl-CoA mutase or related pathways. Patients with MMA are unable to properly break down specific compounds, leading to accumulation of toxic substances in the blood, which can result in developmental delays, recurrent metabolic crises, and…
Methylmalonic Acid Market: An In-Depth Analysis
In 2024, the market was valued at approximately USD 250 million and is projected to reach around USD 400 million by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
Methylmalonic Acid Market Overview
Methylmalonic acid serves as a crucial biomarker in clinical settings, aiding in the diagnosis of conditions such as methylmalonic acidemia and other vitamin B12-related disorders. The market's growth is fueled by the rising…
Methylmalonic Acidemia (MMA) Market Size Projected To Reach $12.5 Billion By 203 …
The Methylmalonic Acidemia (MMA) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Methylmalonic Acidemia (MMA) Market?
The market for methylmalonic acidemia (MMA) has experienced robust growth in the past few years. The size of the market is forecasted to…
Methylmalonic Acidemia Market 2023 Trends, Top Industry Players and Future Trend …
"According to the research report, the global methylmalonic acidemia market was valued at USD 9.16 billion in 2022 and is expected to reach USD 14.78 billion by 2032, to grow at a CAGR of 5.0% during the forecast period."
Get Sample with Latest Trends and Future Advancements @ https://www.polarismarketresearch.com/industry-analysis/methylmalonic-acidemia-market/request-for-sample
Polaris Market Research has recently published its latest analysis on Methylmalonic Acidemia Market 2023: By Types, Applications, Size, Share, Key Players & Regions…
Methylmalonic Acid Market Will Generate Record Revenue by 2029
The Methylmalonic Acid Market is anticipated to grow at a significant CAGR during the forecast period. Methylmalonic acid (MMA) is a substance created by the human body when it digests protein. The amount of vitamin B12 in the body controls the production of MMA in the body. A high amount of MMA typically means a deficiency of vitamin B12.?The major factor driving the growth of the market during the forecast…
Methylmalonic Acidemia Market to Show a Rise During the Forecast Period asserts …
DelveInsight's "Methylmalonic Acidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Methylmalonic Acidemia, historical and forecasted epidemiology as well as the Methylmalonic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Methylmalonic Acidemia market report provides current treatment practices, emerging drugs, Methylmalonic Acidemia market share of the individual therapies, and current and forecasted Methylmalonic Acidemia market size…
